Help
RSS
API
Feed
Maltego
Contact
Domain > bdpartners-asia.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2020-04-26
116.126.87.13
(
ClassC
)
2025-11-03
49.236.137.137
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Mon, 03 Nov 2025 14:55:29 GMTServer: ApacheConnection: closeTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8 !DOCTYPE html>html langko> head> meta http-equivcontent-type contenttext/html; charsetUTF-8> meta http-equivX-UA-Compatible contentIEEdge> meta nameviewport contentwidthdevice-width, initial-scale1.0> meta namedescription contentbdpartners-asia is a Business Development Partnering firm bridging Asian innovators among China, ASEAN, Japan, and Korea> meta nameauthor contentwhois> link relshortcut icon href/data/file/favicon_1.ico /> title>bdpartners-asia/title> !-- Google-Fonts --> link hrefhttps://fonts.googleapis.com/css?familyNoto+Sans+TC:100,300,400,500,700,900&displayswap relstylesheet> link hrefhttp://fonts.googleapis.com/css?familyRoboto+Slab:400,300,700 relstylesheet typetext/css> !--external css--> link href/common/images/css/simple-line-icons.css?v202003300000 relstylesheet /> !--popups css--> link href/common/images/css/magnific-popup.css?v202003300000 relstylesheet typetext/css> link hrefhttp://fonts.googleapis.com/css?familyOpen+Sans:400,300,600,700,800 relstylesheet typetext/css> !-- CSS --> !-- Twitter Bootstrap css --> !-- link relstylesheet href/data/tpl/css/bootstrap.min.css?v202003300000> --> link relstylesheet href/common/images/css/bootstrap.css?v202003300000> !-- jquery.fancybox --> link relstylesheet href/data/tpl/css/jquery.fancybox.css?v202003300000> !-- animate --> link relstylesheet href/data/tpl/css/animate.css?v202003300000> !-- Main Stylesheet --> link relstylesheet href/data/tpl/css/main.css?v202003300000> !-- media-queries --> link relstylesheet href/data/tpl/css/media-queries.css?v202003300000> link relstylesheet href/data/tpl/css/owl.carousel.css?v202003300000> !-- Modernizer Script for old Browsers --> script src/data/tpl/js/modernizr-2.6.2.min.js?v202003300000>/script> !-- Fontawesome Icon font --> link relstylesheet hrefhttps://use.fontawesome.com/releases/v5.2.0/css/all.css> !-- user common css --> !-- /user common css --> !-- Custom styles for this template --> link href/common/images/css/YTPlayer.css?v202003300000 relstylesheet typetext/css /> !-- HTML5 shim and Respond.js IE8 support of HTML5 tooltipss and media queries --> !--if lt IE 9> script src/common/images/js/html5shiv.js?v202003300000>/script> script src/common/images/js/respond.min.js?v202003300000>/script> !endif--> link href/tpl/common.css?v202003300000 typetext/css relstylesheet /> script typetext/javascript src/common/js/sky.rama.js?v202003300000>/script> !-- Main jQuery --> script src/data/tpl/js/jquery-1.11.1.min.js?v202003300000>/script> script typetext/javascript src/common/js/jquery/jquery-migrate-1.3.0.min.js?v202003300000>/script> script typetext/javascript src/common/js/i18n/jquery.i18n.properties-min-1.0.9.js?v202003300000>/script> script typetext/javascript src/?actcommon.set_langvar&v201510020000>/script> script typetext/javascript src/common/js/durian.common.js?v202003300000>/script> script typetext/javascript src/common/js/jquery/jquery-ui.custom.min.js?v202003300000>/script> script typetext/javascript src/common/js/jquery/jquery.blockUI.js?v202003300000>/script> script typetext/javascript src/data/tpl/js/jquery.easy-ticker.js?v202003300000>/script> !-- js --> script typetext/javascript> var SITE_ID bdpartners; var IMG_SERVER ; /script> !-- /js --> !-- user js --> !-- script typetext/javascript src/data/tpl/common.js?v202003300000>/script> --> !-- /user js --> /head> body idbody> !-- preloader --> !-- div idpreloader> img src/images/basic_resp/img/preloader.gif altPreloader> /div> --> !--AREA_TOP_START--> !--L_TOP_MENU-->header idnavigation classnavbar-fixed-top navbar>div classcontainer> div classnavbar-header> !-- responsive nav button --> button typebutton classnavbar-toggle data-togglecollapse data-target.navbar-collapse> span classsr-only>Toggle navigation/span> i classfa fa-bars fa-2x>/i> /button> !-- /responsive nav button --> !-- logo --> a classnavbar-brand href#body> !-- img src/data/tpl/img/logo_over.png altlogo> --> /a> !-- /logo --> /div> !-- main nav --> nav classcollapse navbar-collapse navbar-right rolenavigation> ul idnav classnav navbar-nav> li classcurrent>a href#body>Main/a>/li> li>a href#AboutUs>About us/a>/li> li>a href#Environment>Your Environment/a>/li> li>a href#Service>Our Service/a>/li> li>a href#PartneringHistory>Partnering History/a>/li> li>a href#Contact>Contact/a>/li> /ul> /nav> !-- /main nav --> /div>/header>!--L_TOP_MENU--> !--L_MAIN_IMAGE-->section idslider> div idcarousel-example-generic classcarousel slide data-ridecarousel> !-- Indicators bullet --> ol classcarousel-indicators> li data-target#carousel-example-generic data-slide-to0 classactive>/li> li data-target#carousel-example-generic data-slide-to1>/li> li data-target#carousel-example-generic data-slide-to2>/li> li data-target#carousel-example-generic data-slide-to3>/li> /ol> !-- End Indicators bullet --> !-- Wrapper for slides --> div classcarousel-inner rolelistbox> h2 data-wow-duration1000ms data-wow-delay700ms classwow fadeIn animated>span>BD Partners Asia/span>/h2> p data-wow-duration1300ms classwow slideInRight animated> is a Business Development Partnering firm bridging Asian innovators among China, ASEAN, Japan, and Koreabr> - has tremendous track records among China/ASEAN’s majors and leading biotechsbr> having pharmaceutical assets of i) oncology, ii) immunology, iii) infectious disease, & iv) metabolic diseasebr> - connects remotely the best point of BD community. /p> !-- single slide --> div classitem active overlay2 stylebackground-image: url(/data/tpl/img/main_img04.jpg);> div classcarousel-caption> !-- h2 data-wow-duration700ms data-wow-delay500ms classwow bounceInDown animated>BDspan> Partners/span> Asia/h2> --> h3 data-wow-duration1200ms classwow slideInLeft animated>span classcolor>Shanghai/span>/h3> /div> /div> !-- end single slide --> !-- single slide --> div classitem overlay2 stylebackground-image: url(/data/tpl/img/main_img02.jpg);> div classcarousel-caption> h3 data-wow-duration1200ms classwow slideInLeft animated>span classcolor>Nanjing/span>/h3> /div> /div> !-- end single slide --> !-- single slide --> div classitem overlay2 stylebackground-image: url(/data/tpl/img/main_img03.jpg);> div classcarousel-caption> h3 data-wow-duration1200ms classwow slideInLeft animated>span classcolor>Seoul/span>/h3> /div> /div> !-- end single slide --> !-- single slide --> div classitem overlay2 stylebackground-image: url(/data/tpl/img/main_img01.jpg);> div classcarousel-caption> h3 data-wow-duration1200ms classwow slideInLeft animated>span classcolor>Jakartaspan>/h3> /div> /div> !-- end single slide --> /div> !-- End Wrapper for slides --> /div>/section>!--L_MAIN_IMAGE--> !--AREA_TOP_END--> !--AREA_BODY_START--> !--BODY-->section idAboutUs classaboutus> div classcontainer> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h2>About Us/h2> div classdevider>i classfar fa-arrow-alt-circle-down>/i>/div> /div> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h3>Our Scope/h3> /div> div classcol-sm-6 col-md-6 wow fadeInLeft data-wow-duration500ms> div classservice-item> div classservice-icon fa-lg> i classfas fa-cloud>/i> /div> div classservice-desc> h3>Business Development among China/ASEAN/Korea in the field of Pharmaceuticals/Biotechnology:/h3> p> Licensing of technology/productbr>Investment recruitment br>br> /p> /div> /div> /div> div classcol-sm-6 col-md-6 wow fadeInRight data-wow-duration500ms> div classservice-item> div classservice-icon fa-lg> i classfas fa-map-marker-alt>/i> /div> div classservice-desc> h3>Our Competitiveness/h3> p> Regional: BD among China/ASEAN Worldwide to Asia br> Early staged: BD based on innovativenessbr> Remote/non-F2F: introduction based on Connection /p> /div> /div> /div> /div> /div>/section>section classleadership> div classcontainer> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h3>Leadership/h3> /div> div classcol-sm-6 col-md-6 wow fadeInLeft addoption data-wow-duration500ms> div classservice-item> div classservice-icon fa-lg> i classfas fa-user-tie>/i> /div> div classservice-desc> h3>Mr. YoungHoon (Nicholas) Cho,br>Managing Partner: CEO/h3> p> CEIBS (span classchina_font>中欧国际工商学院/span> www.ceibs.edu) Global EMBA ongoingbr> Seoul National Univ. MS, ChungAng Univ. BS in Life Sciencebr> Simcere-Genexine (JV COO), Genexine (BD Director), JW Pharma, Samyang (Korea & US)br>br> /p> /div> /div> /div> !--div classcol-sm-6 col-md-6 wow fadeInRight data-wow-duration500ms> div classservice-item> div classservice-icon fa-lg> i classfas fa-user-tie>/i> /div> div classservice-desc> h3>Mr. Jinyeol Yang,br>Assistant Manager/h3> p> ChungAng Univ. Pharm D.br> Registered Pharmacist in Koreabr> Internship in Intervestbr>br> /p> /div> /div>--> /div> /div> /div>/section>!-- section id classaboutus no-padding> div classcontainer-fluid> div classrow> div classcol-md-3 styleheight:300px;background:url(/data/tpl/img/img01.jpg) 50% 50% / cover no-repeat;>/div> div classcol-md-3 styleheight:300px;background:url(/data/tpl/img/img02.jpg) 50% 50% / cover no-repeat;>/div> div classcol-md-3 styleheight:300px;background:url(/data/tpl/img/img03.jpg) 50% 50% / cover no-repeat;>/div> div classcol-md-3 styleheight:300px;background:url(/data/tpl/img/img04.jpg) 50% 50% / cover no-repeat;>/div> /div> /div>/section> -->section idEnvironment classenvironment> div classparallax-overlay> div classcontainer> div classrow text-center> div classsec-title mb50 wow fadeInDown animated data-wow-duration1000ms> h2>Your Environment/h2> div classdevider2>i classfar fa-arrow-alt-circle-down>/i>/div> /div> div classwow fadeInRight data-wow-duration500ms data-wow-delay900ms> h3>Early stage Biotech company/h3> h4>; its finance environment/h4> p> ROI of Bio-industry is 7 times higher than that of automotive industry.br> However major parts of investment focused on matured Biotech companies (7 years old ~).br>br> Early stage biotech is hard to be invested in relevant stage and relevant amount.br> Among 400 companies, only 2 companies may survive. /p> /div> !-- div classcol-md-6 styleheight:300px;background:url(/data/tpl/img/main_img01.jpg) 50% 50% / cover no-repeat;>/div> --> /div> /div> /div>/section>section classaboutus> div classcontainer> div classrow text-center> div classsec-title mb50 wow fadeInDown animated data-wow-duration1000ms> h3>How to Navigate the Valley of Death/h3> /div> figure classteam-member col-md-6 col-sm-6 col-xs-12 text-center wow fadeInUp animated data-wow-duration500ms> div classmember-thumb> img src/data/tpl/img/enviro_img01.jpg alt classimg-responsive> figcaption classoverlay> ul classsocial-links text-center> li>a href data-togglemodal data-target#myModal>i classfas fa-search-plus>/i>/a>/li> /ul> /figcaption> /div> /figure> div classcol-md-6 text-left classwow fadeInRight data-wow-duration500ms data-wow-delay900ms> p> The Valley of Death may come 3 years after incorporation in the stage of GLP tox/safety.br> Phase Ⅰ requires $ 1~2M / years, 5 years~ (in case of Korea). br>br> /p> h4 classh-padding>strong>Possible solutions/strong>/h4> p> span stylecolor:#9c2929> ⅰ) Special listing of excellent technology companies on the KOSDAQbr> ⅱ) Investment from VC and Angel Awarded by Government Grantbr> ⅲ) Early Stage Licensing-Out M&A /span> /p> br>br> !--p>Ref. The Korean Federation of Science and Technology Societies Issue Paper, Aug/2017/p>--> p>Ref-: The basics of preclinical drug development for neurodegenerative disease indications. Steinmetz KL, Spack EG - BMC Neurol (2009),/p> /div> /div> /div>/section>section id classservice> div classcontainer> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h3>Technology focused IPO/h3> /div> /div> div classrow> ul classlist-group col-md-25 wow fadeInRight data-wow-duration500ms data-wow-delay900ms> li classlist-group-item text-center color2>Tech Excellencediv classbr>br>/div>/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>L/O performance/td> /tr> tr> td>•/td> td>Funding by Strategic Investors/td> /tr> tr> td>•/td> td>Collaborative research network/td> /tr> tr> td>•/td> td>Originality of tech./td> /tr> tr> td>•/td> td>Government project performance/td> /tr> /tbody> /table> /li> /ul> ul classlist-group col-md-25 wow fadeInRight data-wow-duration800ms data-wow-delay900ms> li classlist-group-item text-center color3>Tech & Develop. Capability/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Multiple Pipelines/td> /tr> tr> td>•/td> td>Stage of clinical development/td> /tr> tr> td>•/td> td>Commercialization capability of technology/td> /tr> /tbody> /table> div classbr high1>/div> /li> /ul> ul classlist-group col-md-25 wow fadeInRight data-wow-duration1100ms data-wow-delay900ms> li classlist-group-item text-center color4>R&D Capabilitydiv classbr>br>/div>/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Expertise of top management (CEO)/td> /tr> tr> td>•/td> td>Track Record of core scientist(s)/td> /tr> /tbody> /table> div classbr high2>/div> /li> /ul> ul classlist-group col-md-25 wow fadeInRight data-wow-duration1100ms data-wow-delay900ms> li classlist-group-item text-center color5>Intellectual Property/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Patent status of proprietary technology/td> /tr> tr> td>•/td> td>Freedom To Operate (FTO) of IP./td> /tr> /tbody> /table> div classbr high3>/div> /li> /ul> ul classlist-group col-md-25 wow fadeInRight data-wow-duration1100ms data-wow-delay900ms> li classlist-group-item text-center color6>Commercial Value Creation/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Competitors’ status in market/td> /tr> tr> td>•/td> td>Profit model based on Global /domestic competitiveness/td> /tr> tr> td>•/td> td>Absolute market Size/td> /tr> /tbody> /table> div classbr high4>/div> /li> /ul> ul classlist-group col-md-12 wow fadeInRight data-wow-duration1400ms data-wow-delay900ms> li classlist-group-item text-center color7>Successful Next Funding/li> /ul> /div> /div>/section>section idImplication classImplication> div classparallax-overlay2> div classcontainer> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h3>Implication/h3> /div> /div> div classrow> div classcol-md-5> div classround_wrap> div classround1 wow fadeInDown animated data-wow-duration1000ms> h4>Licensing Out/h4> /div> div classround2 wow fadeInDown animated data-wow-duration1200ms> h4>Funding by Strategic Investor/h4> /div> div classround3 wow fadeInDown animated data-wow-duration1400ms> h4>Value Increase of Portfolio/h4> /div> div classround4 wow fadeInDown animated data-wow-duration1600ms> h4>Trial Collaboration/h4> /div> /div> /div> div classcol-md-2 text-center> div classround_arrow>h1>i classfar fa-arrow-alt-circle-right>/i>/h1>/div> div classround_arrow_m>h1>i classfar fa-arrow-alt-circle-down>/i>/h1>/div> /div> div classcol-md-5 text-center> div classround5 wow fadeInDown animated data-wow-duration1000ms> h3>Overseas Partnershipbr>with Strategic Investorsbr>especially with Pharma/h3> /div> /div> /div> /div> /div>/section>section idService classservice> div classcontainer> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h2>Our Service/h2> div classdevider>i classfar fa-arrow-alt-circle-down>/i>/div> /div> div classcol-md-12 mb50 wow fadeInRight data-wow-duration500ms data-wow-delay900ms> h3 classtext-center>Key Success Factors of early stage L/O/h3> /div> /div> div classrow> ul classlist-group col-md-4 wow fadeInRight data-wow-duration500ms data-wow-delay900ms> li classlist-group-item text-center color2>Maximize Asset value/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Categorization of Assetbr>- Make it bigger/td> /tr> tr> td>•/td> td>Open Deal Structure br>- FTE reward/td> /tr> tr> td>•/td> td>Make it grow by PFCbr>(Project Focusing Company)/td> /tr> /tbody> /table> /li> /ul> ul classlist-group col-md-4 wow fadeInRight data-wow-duration800ms data-wow-delay900ms> li classlist-group-item text-center color3>Focus on L/O Market/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Focus on future market, not on existing products/td> /tr> tr> td>•/td> td>Focus on their needs, not to our capability/td> /tr> tr> td>•/td> td>Benchmarking/td> /tr> /tbody> /table> div classbr>br>br>/div> /li> /ul> ul classlist-group col-md-4 wow fadeInRight data-wow-duration1100ms data-wow-delay900ms> li classlist-group-item text-center color4>Deal Fluency/li> li classlist-group-item> table classtable no-border> thead> col width10>/col> col>/col> /thead> tbody> tr> td>•/td> td>Importance of Front Linebr>- Pattern, Capability/td> /tr> tr> td>•/td> td>Location of experts br>- China / Koreabr>- Connection/td> /tr> /tbody> /table> div classbr high5>/div> /li> /ul> ul classlist-group col-md-12 wow fadeInRight data-wow-duration1400ms data-wow-delay900ms> li classlist-group-item text-center color7>L/O success in early stage, Investment from strategic investors/li> /ul> /div> /div>/section>section idPartneringHistory classaboutus> div classcontainer-fluid> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h2>Partnering History/h2> div classdevider>i classfar fa-arrow-alt-circle-down>/i>/div> /div> div classcol-md-12 wow fadeInRight data-wow-duration500ms data-wow-delay900ms> div classrow> div classmap_img_all> img src/data/tpl/img/map_all.jpg width100%> /div> div classmap_img> div classcol-md-6> img src/data/tpl/img/map.jpg width100%> /div> div classcol-md-6> ul classmedia-list> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo01.png alt...> /div> div classmedia-body> p classmedia-heading>Genexine’s Licensing deal for China rights on GX-E4, with Chemo-Wanbang in Fosun Group (2016).br>Currently in clinical study in China/p> /div> /li> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo02.png alt...> /div> div classmedia-body> p classmedia-heading>Genexine’s licensing deal for ASEAN & Australia right on GX-E4 with Kalbe Group–ASEAN`s leading pharma (2015).br>Currently in Phase III, 7 countries including Australia/p> /div> /li> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo03.png alt...> /div> div classmedia-body> p classmedia-heading>Genexine’s licensing deal for China rights on multi products With Tasgen in Tasly Group (2015). Listed on NASDAQ as I-Mab (2020), Lead product is in Phase II China/p> /div> /li> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo04.png alt...> /div> div classmedia-body> p classmedia-heading>Genexine’s HPV DNA vaccine licensing With Simnogen in Simcere Group (2014).br>JV backed co-development/p> /div> /li> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo05.png alt...> /div> div classmedia-body> p classmedia-heading>Samyang’s siRNA technology co-development agreement (2011).br>Samyang is a Korean conglomerate having Samyang Biopharma/p> /div> /li> li classmedia> div classmedia-left> img classmedia-object src/data/tpl/img/map_logo06.png alt...> /div> div classmedia-body> p classmedia-heading>BD activity collaboration Asia wide located in Shanghai / Hong Kong/p> /div> /li> /ul> /div> /div> /div> /div> /div> /div>/section>section idContact classcontact> div classcontainer-fluid> div classrow> div classsec-title text-center mb50 wow fadeInDown animated data-wow-duration1000ms> h2>Contact/h2> div classdevider>i classfar fa-arrow-alt-circle-down>/i>/div> /div> div classcol-md-6> div classrow> div classoverlay3 styleheight:150px;background:url(/data/tpl/img/location_img01.jpg) 50% 50% / cover no-repeat;> h3 classtext-center white>Korea (HQ)/h3> /div> div classcontact-desc text-right> p> 70 Saechang-ro, Suite#106-1303, Yongsan-gu, Seoul 04354, Koreabr> 서울특별시 용산구 새창로 70, 106동 1303호, (우편번호 04354)br>br> a hrefmailto:info@bdpartners-asia.com classmail>i classfar fa-envelope>/i> info@bdpartners-asia.com/a>br>br> /p> /div> /div> /div> div classcol-md-6> div classrow> div classoverlay3 styleheight:150px;background:url(/data/tpl/img/location_img02.jpg) 50% 50% / cover no-repeat;> h3 classtext-center white>China/h3> /div> div classcontact-desc> p> 602 Pengjiang Road, Building C, Suite 105, Shanghai 200072br> span classchina_font>上海市静安区彭江路602号C座105室 邮政编码 200072/span>br>br> a hrefmailto:info@bdpartners-asia.com classmail>i classfar fa-envelope>/i> info@bdpartners-asia.com/a> /p> /div> /div> /div> /div> /div>/section>!-- Image modal -->div classmodal fade idmyModal tabindex-1 roledialog aria-labelledbymyModalLabel aria-hiddentrue> div classmodal-dialog modal-lg> div classmodal-content> div classmodal-body> img src/data/tpl/img/enviro_img01.jpg alt classimg-responsive> /div> div classmodal-footer> button typebutton classbtn btn-default data-dismissmodal>Close/button> /div> /div> /div>/div>!--BODY--> !--AREA_BODY_END--> !--AREA_BOTTOM_START--> !--L_FOOTER-->footer idfooter classfooter> div classcontainer> div classrow> div classcol-md-12 wow fadeInUp animated data-wow-duration500ms> div classfooter-single text-center> img src/data/tpl/img/logo.png altf_logo> /div> /div> /div> div classrow> div classcol-md-12> p classcopyright text-center> Copyright © BD Partners Asia, Inc. a hrefwww.bdpartners-asia.com>www.bdpartners-asia.com/a>br> info@bdpartners-asia.com /p> /div> /div> /div>/footer>a hrefjavascript:void(0); idback-top>i classfa fa-angle-up fa-3x>/i>/a>!--L_FOOTER--> !--AREA_BOTTOM_END--> !-- Back to top --> !-- JavaScript --> !-- Placed at the end of the document so the pages load faster --> !-- initialize jQuery Library --> !--script src/common/images/js/jquery.min.js?v202003300000>/script>--> !--script src/common/images/plugins/jquery-ui/jquery-ui.min.js?v202003300000>/script>--> !-- SmoothScroll --> !-- Video --> script src/common/images/js/jquery.mb.YTPlayer.js?v202003300000>/script> !--popup js--> script src/common/images/js/jquery.magnific-popup.min.js?v202003300000 typetext/javascript>/script> !-- Parallax --> script src/common/images/js/jquery.stellar.min.js?v202003300000>/script> script typetext/javascript> !-- cross browser --> window.requestAnimationFrame||(window.requestAnimationFramefunction(){return window.webkitRequestAnimationFrame||window.mozRequestAnimationFrame||window.oRequestAnimationFrame||window.msRequestAnimationFrame||function(n){window.setTimeout(n,1e3/60)}}()); /script> !-- Typed --> script src/common/images/js/typed.js?v202003300000 typetext/javascript>/script> !-- Custom --> script src/common/images/js/app.js?v202003300000 typetext/javascript>/script> !-- Essential jQuery Plugins --> !-- Main jQuery --> !-- Single Page Nav --> script src/data/tpl/js/jquery.singlePageNav.min.js?v202003300000>/script> !-- Twitter Bootstrap --> script src/data/tpl/js/bootstrap.min.js?v202003300000>/script> !-- jquery.fancybox.pack --> script src/data/tpl/js/jquery.fancybox.pack.js?v202003300000>/script> !-- jquery.mixitup.min --> script src/data/tpl/js/jquery.mixitup.min.js?v202003300000>/script> !-- jquery.parallax --> script src/data/tpl/js/jquery.parallax-1.1.3.js?v202003300000>/script> !-- jquery.countTo --> script src/data/tpl/js/jquery-countTo.js?v202003300000>/script> !-- jquery.appear --> script src/data/tpl/js/jquery.appear.js?v202003300000>/script> !-- Contact form validation --> script srchttp://cdnjs.cloudflare.com/ajax/libs/jquery.form/3.32/jquery.form.js>/script> script srchttp://cdnjs.cloudflare.com/ajax/libs/jquery-validate/1.11.1/jquery.validate.min.js>/script> !-- Google Map --> script typetext/javascript srchttp://maps.googleapis.com/maps/api/js?sensorfalse>/script> !-- jquery easing --> script src/data/tpl/js/jquery.easing.min.js?v202003300000>/script> !-- jquery easing --> script src/data/tpl/js/wow.min.js?v202003300000>/script> script> var wow new WOW ({ boxClass: wow, // animated element css class (default is wow) animateClass: animated, // animation css class (default is animated) offset: 120, // distance to the element when triggering the animation (default is 0) mobile: false, // trigger animations on mobile devices (default is true) live: true // act on asynchronously loaded content (default is true) } ); wow.init(); /script> !-- Custom Functions --> script src/data/tpl/js/custom.js?v202003300000>/script> /body>/html>script typetext/javascript> var isMain true; /script>div styledisplay:none;>!----------------------------- START 2025-11-03 23:55:30 INIT : 0.00538 EXEC : 0.00663 LAYOUT : 0.00199 END : 0.00630--------------------------- TOTAL : 0.02031----------------------------->/div>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]